SMARTool Annual Report M1-M12

Overview of the project results The first 12 months of SMARTool have been dedicated to: 1. Completing the activities planned to achieve the milestones of the first year for WP6, dissemination-exploitation (M6.1) and WP7, management (M7.1, M7.2) as reported in deliverables D6.1, D6.3 and D6.6, all submitted in due time; 2. Completing the planned clinical activity of WP1, as reported in deliverable D1.1, submitted on month 7, which includes the clinical study protocol, ethics application and selection of patients for follow up study under appropriate eligibility and exclusion criteria (clinical and technical) ; 3. Advancing towards the achievement of three scientific milestones (MS1.1, MS 2.1 and MS 2.3, month 18), through a devised and well-coordinated execution of tasks and sub-tasks of WP1 and WP2 as stated among Consortium partners and clinical Third Parties hospital centers in the first Clinical-Technical Meeting (June 2016) . 4. Reaching a definite agreement among all Partners at the first Technical Meeting (November 2016) on the overall ICT platform architecture (the main Project outcome) and plan the next activities required to achieve the objectives of WP1 and WP2 to reach MS1.1-2.3 , i.e. patient specific imaging (CCTA) and non-imaging (clinical, genetics and circulatory markers) data collection at two time points (retrospective-baseline and prospective-follow up. These objectives will be reached through: ? A unified agenda and workplan of follow up evaluation of selected patient for SMARTool study in all clinical centers, based on the initial experience of FTGM-CNR patient recall (24 cases) ? A unified online data entry gateway (CRFA) to collect and organize all imaging and non imaging data of the selected population to be recalled. ? A secure on cloud storage of imaging and non imaging patient information (baseline and follow up) and data sharing among Consortium partners.